NAS:NSTG (USA) Also trade in: Germany

NanoString Technologies Inc

$ 26.45 0 (0%)
Volume: 283,898 Avg Vol (1m): 515,807
Market Cap $: 927.04 Mil Enterprise Value $: 843.58 Mil
P/E (TTM): 0.00 P/B: 8.84
Earnings Power Value -12.24
Net Current Asset Value 1.77
Tangible Book 3
Projected FCF -11.57
Median P/S Value 15.56
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 2.42
Cash-To-Debt ranked lower than
79.87% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
NSTG: 2.42
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.61, Med: 1.67, Max: 5.76
Current: 2.42
0.61
5.76
Equity-to-Asset 0.43
Equity-to-Asset ranked lower than
91.74% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
NSTG: 0.43
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -3.62, Med: 0.3, Max: 0.73
Current: 0.43
-3.62
0.73
Debt-to-Equity 0.62
Debt-to-Equity ranked lower than
98.40% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
NSTG: 0.62
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -15.63, Med: 0.93, Max: 140.8
Current: 0.62
-15.63
140.8
Debt-to-EBITDA -0.88
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
NSTG: -0.88
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.45, Med: -0.87, Max: -0.21
Current: -0.88
-1.45
-0.21
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.91
DISTRESS
GREY
SAFE
Beneish M-Score 4.61
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -877.29%
WACC 11.71%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -64.67
Operating Margin ranked higher than
57.95% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
NSTG: -64.67
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -110.59, Med: -65.81, Max: -33.24
Current: -64.67
-110.59
-33.24
Net Margin % -71.94
Net Margin ranked higher than
57.32% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
NSTG: -71.94
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -108.85, Med: -72.74, Max: -37.91
Current: -71.94
-108.85
-37.91
ROE % -184.39
ROE ranked lower than
86.45% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
NSTG: -184.39
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -289.6, Med: -166.22, Max: -131.19
Current: -184.39
-289.6
-131.19
ROA % -53.89
ROA ranked lower than
58.86% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
NSTG: -53.89
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -88.94, Med: -55.79, Max: -33.11
Current: -53.89
-88.94
-33.11
ROC (Joel Greenblatt) % -387.62
ROC (Joel Greenblatt) ranked higher than
58.40% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
NSTG: -387.62
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -471.86, Med: -278.07, Max: -195.37
Current: -387.62
-471.86
-195.37
3-Year Total Revenue Growth Rate 19.40
3-Year Revenue Growth Rate ranked higher than
78.03% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
NSTG: 5.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -63.6, Med: -20.6, Max: 22
Current: 5.1
-63.6
22
3-Year Total EBITDA Growth Rate -18.90
3-Year EBITDA Growth Rate ranked higher than
66.46% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
NSTG: -4.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -4.7, Med: 31.75, Max: 58.1
Current: -4.7
-4.7
58.1
3-Year EPS w/o NRI Growth Rate -5.00
3-Year EPS w/o NRI Growth Rate ranked higher than
59.63% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
NSTG: -5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 4.75, Max: 61.8
Current: -5
0
61.8

» NSTG's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:NSTG

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare NAS:RYTM SAU:2070 ROCO:4174 NAS:DRNA NAS:DCPH NAS:VNDA NAS:WVE NAS:CBAY TSX:ADVZ NAS:NITE NAS:KNSA TSX:PLI XPAR:ALCLS NAS:OMER OSTO:HNSA NAS:ANIP NAS:MGNX NAS:CERS SHSE:603896 SHSE:603590
Traded in other countries 0F1.Germany
Address 530 Fairview Avenue North, Seattle, WA, USA, 98109
NanoString Technologies Inc is a biotechnology company involved in translational research and molecular diagnostics. The product portfolio is based on a novel digital molecular barcoding technology. This technology, nCounter Analysis System, uses molecular "barcodes" and single-molecule imaging to distinguish and count hundreds of unique transcripts in a single reaction. This system is used for performing cancer research, biomarker validation and screening, and next-generation sequencing validation.

Ratios

Current vs industry vs history
PB Ratio 8.84
PB Ratio ranked lower than
97.09% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
NSTG: 8.84
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.74, Med: 8.6, Max: 973.53
Current: 8.84
2.74
973.53
PS Ratio 6.98
PS Ratio ranked higher than
80.99% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
NSTG: 6.98
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.14, Med: 4.1, Max: 7.79
Current: 6.98
0.14
7.79
EV-to-EBIT -11.69
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
NSTG: -11.69
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -11.88, Med: -6.5, Max: -2.5
Current: -11.69
-11.88
-2.5
EV-to-EBITDA -12.52
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
NSTG: -12.52
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -12.8, Med: -7, Max: -2.6
Current: -12.52
-12.8
-2.6
EV-to-Revenue 7.59
EV-to-Revenue ranked higher than
79.12% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
NSTG: 7.59
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.2, Med: 4.35, Max: 8.4
Current: 7.59
1.2
8.4
Current Ratio 4.83
Current Ratio ranked lower than
68.62% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
NSTG: 4.83
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.85, Med: 3.39, Max: 6.97
Current: 4.83
1.85
6.97
Quick Ratio 4.48
Quick Ratio ranked lower than
71.51% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
NSTG: 4.48
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.41, Med: 2.9, Max: 6.52
Current: 4.48
1.41
6.52
Days Inventory 152.12
Days Inventory ranked lower than
72.35% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
NSTG: 152.12
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 65.26, Med: 137.79, Max: 193.89
Current: 152.12
65.26
193.89
Days Sales Outstanding 59.28
Days Sales Outstanding ranked higher than
56.74% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
NSTG: 59.28
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 52.78, Med: 78.74, Max: 114.89
Current: 59.28
52.78
114.89
Days Payable 65.97
Days Payable ranked lower than
54.85% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
NSTG: 65.97
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 45.31, Med: 60.58, Max: 86.76
Current: 65.97
45.31
86.76

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -16.40
3-Year Share Buyback Rate ranked higher than
54.49% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
NSTG: -16.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -283.9, Med: -15.1, Max: -10.3
Current: -16.4
-283.9
-10.3

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 8.82
Price-to-Tangible-Book ranked lower than
95.53% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
NSTG: 8.82
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 3.58, Med: 8.01, Max: 741.18
Current: 8.82
3.58
741.18
Price-to-Median-PS-Value 1.70
Price-to-Median-PS-Value ranked higher than
58.70% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
NSTG: 1.7
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.04, Med: 0.99, Max: 1.73
Current: 1.7
0.04
1.73
Earnings Yield (Joel Greenblatt) % -8.57
Earnings Yield (Greenblatt) ranked lower than
60.68% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
NSTG: -8.57
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -40.6, Med: -15.3, Max: -8.42
Current: -8.57
-40.6
-8.42

More Statistics

Revenue (TTM) (Mil) $ 111.34
EPS (TTM) $ -2.73
Beta 1.58
Volatility % 69.03
52-Week Range $ 11.12 - 31.25
Shares Outstanding (Mil) 35.05

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N